International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-5 doi: 10.5281/zenodo.13837330
Original Research Article
A Prospective Study to Evaluate the Toxicity and Efficacy of EGCG in Preventing Acute Radiation Dermatitis
Published
Sept. 25, 2024
Abstract

Background: Nearly 75% of all solid cancer patients have to undergo radiation therapy as a part of their treatment of these patients, 95% of patients encounter the problem of radiation dermatitis either during, or after the completion of radiation treatment. Often, this is also associated with patient reported symptoms such as pain at local site and tightness of the skin. There are no topical or oral agents that has shown promise in prevention of radiation dermatitis. Our primary objective of this study was to look into the safety and efficacy of topical green tea extract for prevention of radiation dermatitis. Secondary objective was to validate the curative properties of green tea extract gel. Material and Methods: Topical green tea extract gel was prepared at a concentration of 0.75 mmol/L. 30 consecutive patients treated for solid carcinomas for various subsite were asked to apply the gel on the skin at the site of radiotherapy and at a control site fairly away from site of radiation, thrice daily; at least 2 hours before radiotherapy, 2 hours after radiotherapy and before going to bed in night. Application of green tea extract gel was started from day 1 of radiotherapy treatment and was continued till 2 weeks after the end of radiotherapy treatment. Skin toxicity parameters includes RTOG/EORTC grade of dermatitis; pain at the site of radiation; and tightness at the site of radiation. These were recorded at the end of radiotherapy treatment as well as at the end of 2 weeks after completion of radiotherapy treatment. Results:43 patients were treated in the radiotherapy department from June 2021 to Dec 2021 for various subsites. Of these, initial consecutive 30 patients were taken for the study. This cohort included 11 head and neck cancer patients, 12 breast cancer patients and 7 cervix cancer patients.None of these patients developed cutaneous reaction at the control site, implying the inertness of the green tea extract gel. 29 patients developed any grade of radiation dermatitis at the end of radiotherapy treatment. 1 patient did not developing any dermatitis at the end of radiotherapy treatment (p<0.89). With continuation of green tea extract application, 9 patients fully recovered from dermatitis at the end of 2 weeks post completion of radiotherapy treatment (p<0.001). 17 patients reported nopain at local site at the end of radiotherapy treatment (p<0.03); 15 patients were prevented from tightness at the end of radiotherapy treatment (p<0.05); which were statistically significant. Conclusion:The green tea extract gel shows an excellent safety profile, with none of the patients in our study cohort developing an adverse skin reaction. Topical administration of green tea extract gel, seems to be feasible for treating acute radiation dermatitis. This also seems feasible to both reduce the incidence and treat the new onset pain and tightness of the skin at the radiation site associated with or without acute radiation dermatitis at the site of radiotherapy treatment.

Recommended Articles
Loading Image...
Volume-5, Issue-5
Citations
1792 Views
193 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved